CRNX
Price
$35.61
Change
+$1.36 (+3.97%)
Updated
Sep 5 closing price
Capitalization
3.23B
61 days until earnings call
VRDN
Price
$18.72
Change
+$0.08 (+0.43%)
Updated
Sep 5 closing price
Capitalization
1.53B
73 days until earnings call
Interact to see
Advertisement

CRNX vs VRDN

Header iconCRNX vs VRDN Comparison
Open Charts CRNX vs VRDNBanner chart's image
Crinetics Pharmaceuticals
Price$35.61
Change+$1.36 (+3.97%)
Volume$1.42M
Capitalization3.23B
Viridian Therapeutics
Price$18.72
Change+$0.08 (+0.43%)
Volume$799.78K
Capitalization1.53B
CRNX vs VRDN Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. VRDN commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a StrongBuy and VRDN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (CRNX: $35.61 vs. VRDN: $18.72)
Brand notoriety: CRNX and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 149% vs. VRDN: 103%
Market capitalization -- CRNX: $3.23B vs. VRDN: $1.53B
CRNX [@Biotechnology] is valued at $3.23B. VRDN’s [@Biotechnology] market capitalization is $1.53B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, VRDN is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 5 TA indicator(s) are bullish while VRDN’s TA Score has 3 bullish TA indicator(s).

  • CRNX’s TA Score: 5 bullish, 5 bearish.
  • VRDN’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CRNX is a better buy in the short-term than VRDN.

Price Growth

CRNX (@Biotechnology) experienced а +14.91% price change this week, while VRDN (@Biotechnology) price change was +1.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

CRNX is expected to report earnings on Nov 06, 2025.

VRDN is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($3.23B) has a higher market cap than VRDN($1.53B). VRDN YTD gains are higher at: -2.347 vs. CRNX (-30.354). VRDN has higher annual earnings (EBITDA): -340.62M vs. CRNX (-419.62M). CRNX has more cash in the bank: 1.2B vs. VRDN (563M). VRDN has less debt than CRNX: VRDN (21.3M) vs CRNX (49.9M). CRNX has higher revenues than VRDN: CRNX (1.39M) vs VRDN (305K).
CRNXVRDNCRNX / VRDN
Capitalization3.23B1.53B211%
EBITDA-419.62M-340.62M123%
Gain YTD-30.354-2.3471,293%
P/E RatioN/AN/A-
Revenue1.39M305K456%
Total Cash1.2B563M212%
Total Debt49.9M21.3M234%
FUNDAMENTALS RATINGS
CRNX vs VRDN: Fundamental Ratings
CRNX
VRDN
OUTLOOK RATING
1..100
1366
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
6494
SMR RATING
1..100
9699
PRICE GROWTH RATING
1..100
5344
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRNX's Valuation (86) in the Pharmaceuticals Major industry is in the same range as VRDN (94) in the Biotechnology industry. This means that CRNX’s stock grew similarly to VRDN’s over the last 12 months.

CRNX's Profit vs Risk Rating (64) in the Pharmaceuticals Major industry is in the same range as VRDN (94) in the Biotechnology industry. This means that CRNX’s stock grew similarly to VRDN’s over the last 12 months.

CRNX's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as VRDN (99) in the Biotechnology industry. This means that CRNX’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Price Growth Rating (44) in the Biotechnology industry is in the same range as CRNX (53) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to CRNX’s over the last 12 months.

VRDN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that VRDN’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXVRDN
RSI
ODDS (%)
Bearish Trend 1 day ago
77%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 17 days ago
77%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SUHCX22.19N/A
N/A
DWS Health and Wellness C
FFTYX16.59N/A
N/A
AB Sustainable US Thematic Advisor
FFTMX22.11N/A
N/A
Fidelity Advisor Asset Manager 50% M
MNDIX32.86N/A
N/A
MFS New Discovery I
CGJAX73.09N/A
N/A
Calvert US Large Cap Growth Rspnb Idx A